Teijin applies for Japanese approval of febuxostat
06 January 2010
Ian Haydock
ian.haydock@informa.com
In a spate of filings for new drugs by companies in Japan,
Teijin Pharma has applied for the approval in this market of its gout therapy febuxostat (TMX-67).
The filing is actually a resubmission, as Teijin originally applied for the approval of the selective xanthine oxidase inhibitor in...
Please Login to read the full article.